{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:27:17Z","timestamp":1792762037465,"version":"4.5.0"},"reference-count":38,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,7,4]],"date-time":"2006-07-04T00:00:00Z","timestamp":1151971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Recently introduced chelation regimens that combine deferoxamine (DFO) and deferiprone have been shown to have greater efficacy in promoting iron excretion than either chelator alone and have been associated with rapid reduction of the iron load in the heart and liver, and with reversal of cardiac dysfunction. It is unclear whether this combined therapy could be associated with a reduction in iron load or decline in the severity of iron\u2010induced endocrinopathies. Starting in January 2001, 42 patients with <jats:italic>\u03b2<\/jats:italic>\u2010thalassaemia major, previously maintained on subcutaneous DFO only, were switched to combined treatment with DFO and deferiprone. The primary endpoint was to investigate the effects of this therapy on the glucose metabolism characteristics of this population. Combination therapy markedly decreased ferritin levels (638\u2003\u00b1\u20031345 vs. 2991\u2003\u00b1\u20032093\u2003<jats:italic>\u03bc<\/jats:italic>g\/l, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b7001). Glucose responses were improved at all times during an oral glucose tolerance test, particularly in patients in early stages of glucose intolerance. Glucose quantitative secretion also decreased significantly with combined therapy, while no significant change occurred in insulin levels in any group. Insulin secretion, according to the homeostasis assessment model, markedly increased in all groups, while overall reduction in insulin sensitivity did not reach statistical significance. This study showed that the combination of DFO and deferiprone was associated with an improvement in liver iron deposition and glucose intolerance.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2006.06203.x","type":"journal-article","created":{"date-parts":[[2006,7,5]],"date-time":"2006-07-05T21:48:36Z","timestamp":1152136116000},"page":"438-444","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Effect of enhanced iron chelation therapy on glucose metabolism in patients with <i>\u03b2<\/i>\u2010thalassaemia major"],"prefix":"10.1111","volume":"134","author":[{"given":"Kalistheni","family":"Farmaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Angelopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Anagnostopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Gotsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigorios","family":"Rombopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Tolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,7,18]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200550"},{"key":"e_1_2_5_3_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2337\/diacare.28.suppl_1.S37","article-title":"Diagnosis and classification of diabetes mellitus","volume":"28","author":"American Diabetes Association","year":"2005","journal-title":"Diabetes Care"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2005.05.070"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-005-0660-1"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-005-1920-6"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mph.0000199587.76055.21"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2006.01988.x"},{"key":"e_1_2_5_9_1","article-title":"Glucose metabolism, insulin secretion and insulin sensitivity in juvenile hemochromatosis. A case report and review of the literature","author":"Angelopoulos N.","year":"2006","journal-title":"Experimental and Clinical Endocrinology and Diabetes"},{"issue":"3","key":"e_1_2_5_10_1","first-page":"863","article-title":"Glucose tolerance, insulin secretion and peripheral sensitivity in thalassaemia major","volume":"11","author":"Arrigo T.","year":"1998","journal-title":"Journal of Pediatric Endocrinology and Metabolism"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2933"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409013310902"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-002-1121-7"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.5.850"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3167"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.62.731.831"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.63.1.58"},{"issue":"3","key":"e_1_2_5_18_1","first-page":"867","article-title":"Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemia patients","volume":"11","author":"Gamberini M.R.","year":"1998","journal-title":"Journal of Pediatric Endocrinology and Metabolism"},{"issue":"2","key":"e_1_2_5_19_1","first-page":"285","article-title":"Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center","volume":"2","author":"Gamberini M.R.","year":"2004","journal-title":"Pediatric Endocrinology Reviews"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1867"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.4.671"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1995.tb02683.x"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2005.11.002"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1067\/mlc.2001.116487"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198803313181303"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04240.x"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04772.x"},{"key":"e_1_2_5_29_1","first-page":"1163","article-title":"Combined therapy with deferiprone and desfoerrioxamine in thalassaemia major","volume":"90","author":"Origa R.","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(96)90038-4"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2948"},{"key":"e_1_2_5_32_1","first-page":"489","article-title":"Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassaemia major: a retrospective analysis","volume":"88","author":"Piga A.","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(77)90126-3"},{"key":"e_1_2_5_34_1","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1182\/blood.V86.5.2008.bloodjournal8652008","article-title":"Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassaemic and sickle red blood cells both in vitro and in vivo","volume":"86","author":"Shalev O.","year":"1995","journal-title":"Blood"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.3.295"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02298.x"},{"key":"e_1_2_5_37_1","first-page":"1","article-title":"Diabetes mellitus","volume":"727","author":"WHO Study Group","year":"1985","journal-title":"World Health Organization Technical Report Series"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.01002.x"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.504415"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2006.06203.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2006.06203.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T11:34:29Z","timestamp":1697456069000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2006.06203.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,18]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1111\/j.1365-2141.2006.06203.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2006.06203.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,18]]},"assertion":[{"value":"2006-07-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}